BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Asthma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Asthma\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06189742-1507@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tezspire (tezepelumab): Phase 2 readout est. (NCT06189742)
DESCRIPTION:Tezspire (tezepelumab)\, phase 2\, Asthma.\nStudy: Tezepelumab 
 in Allergic Rhinitis and Asthma Study (TEZARS)\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 zepelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06189742
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07705737-1328@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rademikibart: Phase 2 readout est. (NCT07705737)
DESCRIPTION:Rademikibart\, phase 2\, Chronic Obstructive Pulmonary Disease.
 \nStudy: Rademikibart IV for Acute Asthma and COPD Exacerbation\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rademikibart#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07705737
URL:https://assetmemo.bio/drug/rademikibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301255-1361@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ENV-294: Phase 2 readout est. (NCT07301255)
DESCRIPTION:ENV-294\, phase 2\, Asthma.\nStudy: ENV-294 for Moderate-to-Sev
 ere Asthma: A 12-Week Study in Adults\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/env-294#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0730125
 5
URL:https://assetmemo.bio/drug/env-294#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05692180-1322@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT05692180)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: A Multicentr
 e\, Randomised\, Double-blind\, Parallel Group\, Placebo-controlled\, Time
 -to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benra
 lizumab in Paediatric Patients With Severe Eosinophilic Asthma\nEstimated 
 primary completion: 23 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/benralizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05692180
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07436221-1281@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:AK139: Phase 2 readout est. (NCT07436221)
DESCRIPTION:AK139\, phase 2\, Asthma.\nStudy: A Study to Evaluate the Effic
 acy and Safety of AK139 in Participants With Asthma\nEstimated primary com
 pletion: 27 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ak139#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07436221
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05347771-1356@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dupixent (dupilumab): Phase 2 readout est. (NCT05347771)
DESCRIPTION:Dupixent (dupilumab)\, phase 2\, Asthma.\nStudy: Prevention of 
 Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05347771
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488755-1328@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rademikibart: Phase 3 readout est. (NCT06488755)
DESCRIPTION:Rademikibart\, phase 3\, Asthma.\nStudy: SIM0718 Treatment of A
 sthma Clinical Study\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rademikibart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06488755
URL:https://assetmemo.bio/drug/rademikibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05757102-4142@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270127
SUMMARY:Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol): Phas
 e 3 readout est. (NCT05757102)
DESCRIPTION:Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)\,
  phase 3\, Asthma.\nStudy: A Study to Compare the Efficacy\, Safety and To
 lerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma\nEstima
 ted primary completion: 26 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/fluticasone-furoate-umeclidinium-vilanterol#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05757102
URL:https://assetmemo.bio/drug/fluticasone-furoate-umeclidinium-vilanterol#
 upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671001-1527@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Depemokimab: Phase 3 readout est. (NCT07671001)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: A Study of Depemokimab 
 in Participants of 6 to 11 Years of Age\nEstimated primary completion: 1 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/depemokima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 671001
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06977581-1455@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:tilrekimig: Phase 2 readout est. (NCT06977581)
DESCRIPTION:tilrekimig\, phase 2\, Asthma.\nStudy: A Study to Learn About t
 he Study Medicine Called PF-07275315 in People With Moderate-To-Severe Ast
 hma\nEstimated primary completion: 8 March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06977581
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932263-1426@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270607
DTEND;VALUE=DATE:20270608
SUMMARY:tozorakimab: Phase 2 readout est. (NCT06932263)
DESCRIPTION:tozorakimab\, phase 2\, Asthma.\nStudy: Dose Range Finding Stud
 y to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled
  Asthma on Medium-to-High Dose Inhaled Corticosteroids\nEstimated primary 
 completion: 7 June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tozorakimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06932263
URL:https://assetmemo.bio/drug/tozorakimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676319-1424@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:lunsekimig: Phase 2 readout est. (NCT06676319)
DESCRIPTION:lunsekimig\, phase 2\, Asthma.\nStudy: Study of Lunsekimig (SAR
 443765) Compared With Placebo in Adults With High-risk Asthma\nEstimated p
 rimary completion: 21 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/lunsekimig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06676319
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473779-1507@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06473779)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Open-label S
 tudy to Assess Reduction of Background Asthma Medication While Sustaining 
 Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yr
 s With Severe Asthma.\nEstimated primary completion: 25 June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06473779
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473779-3562@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Airsupra (albuterol / budesonide): Phase 3 readout est. (NCT0647377
 9)
DESCRIPTION:Airsupra (albuterol / budesonide)\, phase 3\, Asthma.\nStudy: O
 pen-label Study to Assess Reduction of Background Asthma Medication While 
 Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patie
 nts 12-80yrs With Severe Asthma.\nEstimated primary completion: 25 June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/albuterol-budeson
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06473779
URL:https://assetmemo.bio/drug/albuterol-budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011524-1337@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:CM512: Phase 2 readout est. (NCT07011524)
DESCRIPTION:CM512\, phase 2\, Asthma.\nStudy: Study of CM512 Injection in S
 ubjects With Moderate-to-severe Asthma\nEstimated primary completion: 21 J
 uly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cm512#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07011524
URL:https://assetmemo.bio/drug/cm512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966479-1535@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:verekitug: Phase 2 readout est. (NCT06966479)
DESCRIPTION:verekitug\, phase 2\, Asthma.\nStudy: A Long-Term Safety and Ef
 ficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asth
 ma (VALOUR)\nEstimated primary completion: September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/verekitug#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06966479
URL:https://assetmemo.bio/drug/verekitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471257-3562@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:Airsupra (albuterol / budesonide): Phase 3 readout est. (NCT0647125
 7)
DESCRIPTION:Airsupra (albuterol / budesonide)\, phase 3\, Asthma.\nStudy: A
  Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in 
 Symptomatic Chinese Adults With Asthma\nEstimated primary completion: 4 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/albuterol
 -budesonide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06471257
URL:https://assetmemo.bio/drug/albuterol-budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307665-3562@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271013
DTEND;VALUE=DATE:20271014
SUMMARY:Airsupra (albuterol / budesonide): Phase 3 readout est. (NCT0630766
 5)
DESCRIPTION:Airsupra (albuterol / budesonide)\, phase 3\, Asthma.\nStudy: E
 valuating the Efficacy and Safety of PT027 Compared With PT007 Administere
 d As Needed in Participants 12 to < 18 Years of Age With Asthma\nEstimated
  primary completion: 13 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/albuterol-budesonide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06307665
URL:https://assetmemo.bio/drug/albuterol-budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07403487-1553@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271025
DTEND;VALUE=DATE:20271026
SUMMARY:RC1416: Phase 2 readout est. (NCT07403487)
DESCRIPTION:RC1416\, phase 2\, Asthma.\nStudy: Phase II Trial of RC1416 Inj
 ection in Asthma\nEstimated primary completion: 25 October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rc1416#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07403487
URL:https://assetmemo.bio/drug/rc1416#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07532265-1543@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:frevecitinib: Phase 2 readout est. (NCT07532265)
DESCRIPTION:frevecitinib\, phase 2\, Asthma.\nStudy: A Clinical Study to Ev
 aluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With S
 evere Asthma\nEstimated primary completion: 30 November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/frevecitinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07532265
URL:https://assetmemo.bio/drug/frevecitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323654-1407@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:KT-621: Phase 2 readout est. (NCT07323654)
DESCRIPTION:KT-621\, phase 2\, Asthma.\nStudy: A Study of KT-621 Administer
 ed Orally to Adult Participants With Moderate to Severe Eosinophilic Asthm
 a\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/kt-621#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07323654
URL:https://assetmemo.bio/drug/kt-621#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241546-3744@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:ARO-RAGE: Phase 2 readout est. (NCT07241546)
DESCRIPTION:ARO-RAGE\, phase 2\, Asthma.\nStudy: Study of Inhaled ARO-RAGE 
 in Allergen-induced Mild Asthma\nEstimated primary completion: December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/aro-rage#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07241546
URL:https://assetmemo.bio/drug/aro-rage#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098403-3551@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07098403)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Trial of SHR-1905 i
 n Subjects With Severe Uncontrolled Asthma\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felcore
 kibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07098403
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332067-5789@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Xolair (Omalizumab): Phase 2 readout est. (NCT05332067)
DESCRIPTION:Xolair (Omalizumab)\, phase 2\, Asthma.\nStudy: Omalizumab Befo
 re Onset of Exacerbations\nEstimated primary completion: 1 January 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/omalizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05332067
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979323-1527@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280105
DTEND;VALUE=DATE:20280106
SUMMARY:Depemokimab: Phase 3 readout est. (NCT06979323)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: Depemokimab Asthma Imag
 ing and Bronchoscopy Sub-Study\nEstimated primary completion: 5 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/depemokimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06979323
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02570984-5789@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Xolair (Omalizumab): Phase 2 readout est. (NCT02570984)
DESCRIPTION:Xolair (Omalizumab)\, phase 2\, Asthma.\nStudy: Preventing Asth
 ma in High Risk Kids\nEstimated primary completion: 31 January 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/omalizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT02570984
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562466-3771@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:indacaterol maleate / mometasone furoate: Phase 3 readout est. (NCT
 05562466)
DESCRIPTION:indacaterol maleate / mometasone furoate\, phase 3\, Asthma.\nS
 tudy: A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol A
 cetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Th
 an 12 Years of Age With Asthma\nEstimated primary completion: 1 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/indacaterol-male
 ate-mometasone-furoate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05562466
URL:https://assetmemo.bio/drug/indacaterol-maleate-mometasone-furoate#upcom
 ing-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363642-1507@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07363642)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Phase 3b Stu
 dy in Patients With Severe Asthma Treated With Tezepelumab\nEstimated prim
 ary completion: 7 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tezepelumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07363642
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219173-822@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07219173)
DESCRIPTION:Brenipatide\, phase 2\, Asthma.\nStudy: A Study to Evaluate Bre
 nipatide Compared With Placebo in Adult Participants With Uncontrolled Mod
 erate to Severe Asthma\nEstimated primary completion: April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/brenipatide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07219173
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06023589-1507@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06023589)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: A Study to I
 nvestigate the Efficacy and Safety of Tezepelumab Compared With Placebo in
  Children 5 to < 12 Years Old With Severe Asthma\nEstimated primary comple
 tion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 zepelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06023589
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455396-4661@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280814
DTEND;VALUE=DATE:20280815
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT07455396)
DESCRIPTION:Methylprednisolone\, phase 2\, Asthma.\nStudy: Pediatric Asthma
  Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Ver
 sus Methylprednisolone for Pediatric Critical Asthma\nEstimated primary co
 mpletion: 14 August 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/methylprednisolone#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07455396
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07120503-1536@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:WIN378: Phase 2 readout est. (NCT07120503)
DESCRIPTION:WIN378\, phase 2\, Asthma.\nStudy: Study to Evaluate the Safety
 \, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe A
 sthma\nEstimated primary completion: 1 October 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/win378#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07120503
URL:https://assetmemo.bio/drug/win378#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07546981-4243@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281017
DTEND;VALUE=DATE:20281018
SUMMARY:Trimbow (Beclomethasone dipropionate/formoterol fumarate/glycopyrro
 late): Phase 3 readout est. (NCT07546981)
DESCRIPTION:Trimbow (Beclomethasone dipropionate/formoterol fumarate/glycop
 yrrolate)\, phase 3\, Asthma.\nStudy: Efficacy and Safety of CHF 5993 100/
 6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Do
 ses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonist
 s\nEstimated primary completion: 17 October 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/beclomethasone-dipropionate-formoterol-fumara
 te-glycopyrrolate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07546981
URL:https://assetmemo.bio/drug/beclomethasone-dipropionate-formoterol-fumar
 ate-glycopyrrolate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677059-1407@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:KT-621: Phase 2 readout est. (NCT07677059)
DESCRIPTION:KT-621\, phase 2\, Asthma.\nStudy: A Long-term Study of KT-621 
 Administered Orally to Participants With Asthma Previously Enrolled in a K
 T-621 Asthma Study\nEstimated primary completion: December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/kt-621#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07677059
URL:https://assetmemo.bio/drug/kt-621#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191315-1356@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06191315)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Asthma.\nStudy: Efficacy and S
 afety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Whee
 ze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)\nEstimated primary completi
 on: 21 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06191315
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282886-4243@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trimbow (Beclomethasone dipropionate/formoterol fumarate/glycopyrro
 late): Phase 2 readout est. (NCT07282886)
DESCRIPTION:Trimbow (Beclomethasone dipropionate/formoterol fumarate/glycop
 yrrolate)\, phase 2\, Asthma.\nStudy: VENTURI (VENTilation Using Respirato
 ry Imaging)\nEstimated primary completion: 31 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/beclomethasone-dipropionate-formot
 erol-fumarate-glycopyrrolate#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07282886
URL:https://assetmemo.bio/drug/beclomethasone-dipropionate-formoterol-fumar
 ate-glycopyrrolate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07372287-1336@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ocankitug: Phase 3 readout est. (NCT07372287)
DESCRIPTION:Ocankitug\, phase 3\, Asthma.\nStudy: A Phase III Study of CM32
 6 in Subjects With Moderate to Severe Asthma\nEstimated primary completion
 : 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 cankitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07372287
URL:https://assetmemo.bio/drug/ocankitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309614-1356@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07309614)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Asthma.\nStudy: A Study Assess
 ing the Effect of Dupilumab on Inducing Clinical Remission in Asthma\nEsti
 mated primary completion: January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07309614
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780643-3551@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780643)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Study to Investigat
 e the Efficacy and Safety of GSK5784283 Compared With Placebo in Participa
 nts With Uncontrolled Asthma (PERSIST ASTHMA-1)\nEstimated primary complet
 ion: 15 February 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/felcorekibart#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07780643
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782996-3551@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290504
DTEND;VALUE=DATE:20290505
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07782996)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Study to Investigat
 e the Efficacy and Safety of GSK5784283 Compared With Placebo in Participa
 nts With Uncontrolled Asthma (PERSIST ASTHMA-2)\nEstimated primary complet
 ion: 4 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felc
 orekibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07782996
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525375-4297@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Glycopyrronium (PT001): Phase 2 readout est. (NCT07525375)
DESCRIPTION:Glycopyrronium (PT001)\, phase 2\, Asthma.\nStudy: A Phase II S
 tudy to Investigate Lung Function With 2 Different Doses of Inhaled Glycop
 yrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 
 12 Years of Age With Asthma\nEstimated primary completion: 23 May 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/glycopyrronium-pt001#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075253
 75
URL:https://assetmemo.bio/drug/glycopyrronium-pt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772921-1455@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07772921)
DESCRIPTION:tilrekimig\, phase 3\, Asthma.\nStudy: A Study to Learn About t
 he Study Medicine Called Tilrekimig in People With Severe Asthma\nEstimate
 d primary completion: 1 June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tilrekimig#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07772921
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07869043-1455@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290607
DTEND;VALUE=DATE:20290608
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07869043)
DESCRIPTION:tilrekimig\, phase 3\, Asthma.\nStudy: A Study to Learn About t
 he Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe A
 sthma\nEstimated primary completion: 7 June 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07869043
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07934420-4382@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290730
DTEND;VALUE=DATE:20290731
SUMMARY:Pulmicort (Budesonide): Phase 3 readout est. (NCT07934420)
DESCRIPTION:Pulmicort (Budesonide)\, phase 3\, Asthma.\nStudy: An Efficacy 
 and Safety Study to Assess an Inhaled\, Fixed-dose\, Budesonide/Formoterol
  Fumarate in Participants Aged 4 to Less Than 12 Years of Age With Moderat
 e Persistent Asthma\nEstimated primary completion: 30 July 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/budesonide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07934420
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013123-1507@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290818
DTEND;VALUE=DATE:20290819
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07013123)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Potency of H
 DM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in
  HDM Allergic Patients With Severe Asthma\, Treated With Tezepelumab\nEsti
 mated primary completion: 18 August 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07013123
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444567-1322@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20291227
DTEND;VALUE=DATE:20291228
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT07444567)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: Roll-over St
 udy for Participants Who Have Completed a Previous Clinical Study With Ben
 ralizumab (Fasenra) and Benefit From Continued Treatment\nEstimated primar
 y completion: 27 December 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/benralizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07444567
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07456033-1527@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20300923
DTEND;VALUE=DATE:20300924
SUMMARY:Depemokimab: Phase 3 readout est. (NCT07456033)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: A Study of Efficacy and
  Safety of Depemokimab Compared With Placebo in Adults and Adolescents Wit
 h at Risk Type 2 Asthma\nEstimated primary completion: 23 September 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/depemokimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07456033
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06609239-1424@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20310120
DTEND;VALUE=DATE:20310121
SUMMARY:lunsekimig: Phase 2 readout est. (NCT06609239)
DESCRIPTION:lunsekimig\, phase 2\, Asthma.\nStudy: Long-term Safety and Eff
 icacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asth
 ma\nEstimated primary completion: 20 January 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06609239
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761028-1335@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:stapokibart: Phase 2/3 readout est. (NCT05761028)
DESCRIPTION:stapokibart\, phase 2/3\, Asthma.\nStudy: A Study of CM310 in S
 ubjects With Moderate to Severe Asthma\nEstimated primary completion: May 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/stapokibart#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0576102
 8
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
